Myocardial cell damage in human hypertension
Guillem Pons-Lladó, MD*,
Manel Ballester, MD*,
Xavier Borrás, MD*,
Francesc Carreras, MD*,
Ignasi Carrió, MD ,
Joaquín López-Contreras, MD ,
Alex Roca-Cusachs, MD ,
Jaume Marrugat, MD and
Jagat Narula, MD, PhD||
* Servei de Cardiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Servei de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Unitat dHipertensió del Servei de Medicina Interna, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Institut Municipal dInvestigació Mèdica, Barcelona, Spain
|| Division of Cardiology, Allegheny University Hospitals, Philadelphia, Pennsylvania, USA

View larger version (13K):
[in a new window]
|
Figure 1 The correlation between left ventricular ejection fraction and the severity of myocardial damage detected by antimyosin antibody heart-to-lung uptake ratio in those 36 patients in whom reliable measures of ejection fraction by echocardiography were obtained. The area below the horizontal line represents normal range of antimyosin antibody heart-to-lung uptake ratio (<1.55). LV = left ventricular.
|
|

View larger version (14K):
[in a new window]
|
Figure 2 The correlation between the indexed LVM and the severity of myocardial damage detected by antimyosin antibody heart-to-lung uptake ratio in the 39 hypertensive patients. The area below the horizontal line represents the normal range of antimyosin antibody heart-to-lung uptake ratio (<1.55). There was a significant positive correlation between LVM index and the HLR (r = 0.72). Open squares = patients in group I (no LVH), solid squares = patients in group II (asymptomatic patients with LVH) and solid circles = patients in group III (symptomatic patients). HLR = heart-to-lung ratio; LV = left ventricle; LVH = left ventricular hypertrophy; LVM = left ventricular mass.
|
|
|